|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: Anti-Infective Antibodies
La Merie Publishing, Nov 2011, Pages: 160
The present Competitive Intelligence Report about Anti-Infective Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies and human plasma-derived immunoglobulins and hyperimmunes for post-exposure prophylaxis and treatment of infectious diseases as of November 2011. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The emergence of antibiotic resistant microorganisms, lethal viruses and the threat of engineered microorganism have newly stimulated the interest in recombinant antibodies for infectious diseases. Advances in understanding pathogenetic mechanisms and new antibody technologies have further contributed to a growing class of anti-infective antibodies. Apart from recombinant mono- or polyclonal antibodies, human plasma-derived immunoglobulins have their place in the treatment of immunedeficiencies and specific immunoglobulins (hyperimmunes) are part of standard protocols in post-exposure prophylaxis of a number of infectious diseases. Modern plasma-derived immunoglobulins are characterized by improved purification procedures, more convenience (room temperature stable, ready-to-use preparations, new stabilizers, higher concentrated) and new developments.
The report includes a compilation of product portfolios and current active projects in research and development of anti-infective antibodies and immunoglobulins. In addition, the report lists company-specific R&D pipelines product portfolios anti-infective antibodies, immunoglobulins and hyperimmunes. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
Innovations in Combating Infectious Diseases: Opportunities in Therapeutics and Diagnostics through Application of Proteomics, Genomics, Nanotechnology, and Novel Sources of Lead Generation
Stakeholder Opinions: Biologics in Infectious Diseases - Well Defined Target Populations are Key to Commercial Success
Pharmaceuticals Report Bundle
Emerging Microbiology Tests and Companies Developing New Technologies and Products
Future US Microbiology Testing Market Outlook
Anti-Infectives - Global Strategic Business Report
Future Infectious Disease Testing Market: Growth Opportunities and Business Expansion Strategies
Competitor Analysis: Antiviral Antibodies
|
|
|
|
